KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Research & Development (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Research & Development for 15 consecutive years, with $372.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 24.0% year-over-year to $372.2 million, compared with a TTM value of $1.3 billion through Dec 2025, up 17.19%, and an annual FY2025 reading of $1.3 billion, up 17.19% over the prior year.
  • Research & Development was $372.2 million for Q4 2025 at Alnylam Pharmaceuticals, up from $358.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $372.2 million in Q4 2025 and bottomed at $169.9 million in Q1 2022.
  • Average Research & Development over 5 years is $256.3 million, with a median of $257.1 million recorded in 2023.
  • The sharpest move saw Research & Development surged 35.96% in 2021, then decreased 8.61% in 2022.
  • Year by year, Research & Development stood at $229.0 million in 2021, then rose by 14.4% to $262.0 million in 2022, then rose by 3.86% to $272.1 million in 2023, then increased by 10.3% to $300.2 million in 2024, then increased by 24.0% to $372.2 million in 2025.
  • Business Quant data shows Research & Development for ALNY at $372.2 million in Q4 2025, $358.8 million in Q3 2025, and $323.6 million in Q2 2025.